Given that PDGFRA is a transmembrane tyrosine kinase receptor and that these receptors have been shown to be amenable to exploitation as therapeutic targets, it seems reasonable to hypothesise that PDGFRA may constitute a potential target for anticancer therapy in gliomas. This evidence concerns the gene PDGFRA and glioma.